Earnings Summary

Collegium Pharmaceutical Inc’s revenue jumped 9.71% since last year same period to $135.55Mn in the Q2 2023. On a quarterly growth basis, Collegium Pharmaceutical Inc has generated -6.37% fall in its revenue since last 3-months.

Collegium Pharmaceutical Inc’s net profit jumped 350.57% since last year same period to $13.01Mn in the Q2 2023. On a quarterly growth basis, Collegium Pharmaceutical Inc has generated 116.08% jump in its net profits since last 3-months.

Collegium Pharmaceutical Inc’s net profit margin jumped 328.39% since last year same period to 9.6% in the Q2 2023. On a quarterly growth basis, Collegium Pharmaceutical Inc has generated 117.17% jump in its net profit margins since last 3-months.

Collegium Pharmaceutical Inc’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a -30.77% fall from last quarter’s estimates.

Collegium Pharmaceutical Inc’s earning per share (EPS) estimates for the current year stand at -0.17.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Collegium Pharmaceutical Inc’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Collegium Pharmaceutical Inc’s return on equity (ROE) stands at -0.06.